The two classes work opposite ends of one loop. Bone-preservers (bisphosphonates like alendronate and zoledronic acid, plus denosumab) turn down the cells that dig out old bone 1. Bone-builders (teriparatide, abaloparatide, romosozumab) drive the cells that lay down new bone, opening a roughly one-year window where the skeleton actively builds 2. Fill that window, then a preserver locks it in; never open it, and the gain is lost.
The endpoint is actual broken bones, not scan numbers. A once-yearly zoledronic acid infusion takes about 70% off spine fractures and 41% off hip fractures over three years 3; denosumab is similar 1. But for the very-high-risk, building first wins: a year of romosozumab then alendronate cut hip fractures 38% more than two straight years of alendronate 4. The guidelines now say the same: builder first for very-high-risk 5.
The ninety days do three jobs in order: confirm, stratify, start.
You will not feel any of this. There is no symptom to relieve; the payoff is an event that never arrives.
- Weeks: turnover markers shift; the first dose may leave a day or two of flu-like aching.
- Months 6–12: the fracture-risk curves separate from untreated, and a DXA on a builder shows a 13–15% spine gain 2.
- Years: the spine that did not collapse, the hip that did not break at 82, the Christmas at home instead of in rehab.
The fine print — when to skip it, and what people get wrong
The denosumab cliff: miss a dose and the gain rebounds into new spine fractures within a year 8; stopping it needs a zoledronic acid dose to lock the bone in 9. Stopping any builder without a follow-on preserver wastes it too 10.
Bisphosphonate-first is not always right: that was 2005 practice, before the builder trials 5. Calcium and vitamin D support the drug but do not replace it 6. And it is not a women's disease: a third of hip fractures over 50 are in men 6.
Romosozumab carries a boxed heart-attack and stroke warning; avoid it within a year of either 4. Bisphosphonates are skipped in poor kidney function and active oesophageal disease; their jaw and thigh-fracture risks are rare against the fracture risk treated 11.
- 1Cummings et al. (2009). Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. link
- 2Cosman et al. (2016). Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. link
- 3Black et al. (2007). Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine. link
- 4Saag et al. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine. link
- 5Camacho et al. (2020). American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update. Endocrine Practice. link
- 6LeBoff et al. (2022). The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International. link
- 7Kanis et al. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International. link
- 8Cummings et al. (2018). Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. Journal of Bone and Mineral Research. link
- 9Tsourdi et al. (2021). Discontinuation of Denosumab Therapy for Osteoporosis: A Systematic Review and Position Statement by ECTS. Bone. link
- 10Cosman F (2017). Anabolic Therapy and Optimal Treatment Sequences for Patients with Osteoporosis at High Risk for Fracture. Endocrine Practice. link
- 11Khosla S, Hofbauer LC (2017). Osteoporosis treatment: recent developments and ongoing challenges. The Lancet Diabetes & Endocrinology. link
დაკავშირებული სახელმძღვანელოში (15)
- — Carrying heavy loads loads the skeleton too, and that mechanical stress is part of keeping bone from thinning further.
- — Paired with resistance training, daily creatine slows the bone loss this protocol is fighting.
- — The estrogen drop at menopause is a major bone-loss driver; HRT started in time protects the skeleton.
- — Weight-bearing loading like rucking is one of the bone-stimulating habits that supports bone density.
- — Progressive resistance training is the exercise side of protecting bone after an osteoporosis diagnosis.
- — Resistance training is the exercise prescription for protecting bone density, especially through menopause.
- — Correcting a vitamin D shortfall is one of the basics underneath any osteoporosis plan.
- — Vitamin K2 is one of the quiet, decade-scale supports for keeping bone density up.
- — Smoking speeds bone loss and slows fracture healing. Quitting is part of any serious bone plan.
- — Years on a daily acid blocker quietly raise fracture risk — worth flagging while you size up bone loss.
- — Too much preformed vitamin A (retinol from supplements and liver) weakens bone over time — worth auditing if you're managing osteoporosis.
- — When heavy lifting risks fragile bones, restriction training is a lighter way to hold onto muscle.
- — Undiagnosed celiac is a fixable cause of early bone loss; malabsorption is worth ruling out.
- — Bone loss speeds up sharply in this transition — a silent part of the map worth getting a baseline scan for.
- — Rapid weight loss on GLP-1 drugs strips bone along with fat, so fragile bones need the protein-and-lifting plan even more.
Osteoporosis: The First 90 Days
Multiple large pivotal RCTs with hard fracture endpoints (FIT, HORIZON, FREEDOM, FRAME, ARCH, ACTIVE, VERO, STRUCTURE) plus aligned AACE/ACE 2020, Endocrine Society 2019/2020, and BHOF 2022 clinician guidelines (Black 1996, Black 2007, Cummings 2009, Saag 2017, Cosman 2016, Miller 2016, Kendler 2018, Langdahl 2017, Camacho 2020, Eastell 2019, LeBoff 2022).
Hip fracture in adults over 65 carries 20-25% 12-month all-cause mortality (Brauer 2009); pivotal trials show 40-70% relative reductions in hip and vertebral fracture across antiresorptive and anabolic classes, with anabolic-first sequencing delivering 38% lower hip fracture risk vs alendronate over 24 months (Black 2007, Cummings 2009, Saag 2017).
Daily SC self-injection (teriparatide, abaloparatide), monthly in-clinic injections (romosozumab), or annual IV infusion / 6-monthly SC injection (zoledronic acid, denosumab). Add: baseline lab panel, DXA at 1-2 years, ongoing calcium/vitamin D. Minor lifestyle integration, not life-dominating.
Wide range by path: generic oral bisphosphonates ~$0-300/year; denosumab ~$3000-5000/year; anabolic courses (teriparatide, abaloparatide) ~$70 000+ over 24 months; romosozumab ~$23 000 over 12 months. Insurance typically covers anabolics with prior authorisation. Score reflects the substantial cost typical of the very-high-risk anabolic-first path (Camacho 2020).
Vertebral fracture prevention preserves height and forestalls kyphotic posture over decades; the aesthetic component is real but secondary to the medical effect (Black 2007, Cosman 2016).
The 90-day workup commonly surfaces correctable secondary contributors (vitamin D deficiency, hypothyroidism, hypogonadism, coeliac, hypercalciuria) responsible for ~20-30% of cases; the disease itself is silent so the treatment delivers no felt-experience lift in the first 90 days (Camacho 2020, LeBoff 2022).